Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors
Open Access
- 15 July 2022
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (7) , 873
Abstract
The delta opioid receptor is a Gi-protein-coupled receptor (GPCR) with a broad expression pattern both in the central nervous system and the body. The receptor has been investigated as a potential target for a multitude of significant diseases including migraine, alcohol use disorder, ischemia, and neurodegenerative diseases. Despite multiple attempts, delta opioid receptor-selective molecules have not been translated into the clinic. Yet, the therapeutic promise of the delta opioid receptor remains and thus there is a need to identify novel delta opioid receptor ligands to be optimized and selected for clinical trials. Here, we highlight recent developments involving the delta opioid receptor, the closely related mu and kappa opioid receptors, and in the broader area of the GPCR drug discovery research. We focus on the validity and utility of the available delta opioid receptor structures. We also discuss the increased ability to perform ultra-large-scale docking studies on GPCRs, the rise in high-resolution cryo-EM structures, and the increased prevalence of machine learning and artificial intelligence in drug discovery. Overall, we pose that there are multiple opportunities to enable in silico drug discovery at the delta opioid receptor to identify novel delta opioid modulators potentially with unique pharmacological properties, such as biased signaling.Keywords
Funding Information
- National Institute on Alcohol Abuse and Alcoholism (R01AA025368)
This publication has 89 references indexed in Scilit:
- Structure of the δ-opioid receptor bound to naltrindoleNature, 2012
- The delta opioid receptor: an evolving target for the treatment of brain disordersTrends in Pharmacological Sciences, 2011
- Design and synthesis of KNT-127, a δ-opioid receptor agonist effective by systemic administrationBioorganic & Medicinal Chemistry Letters, 2010
- JNJ-20788560 [9-(8-Azabicyclo[3.2.1]oct-3-ylidene)-9H-xanthene-3-carboxylic Acid Diethylamide], a Selective Delta Opioid Receptor Agonist, Is a Potent and Efficacious Antihyperalgesic Agent That Does Not Produce Respiratory Depression, Pharmacologic Tolerance, or Physical DependenceThe Journal of Pharmacology and Experimental Therapeutics, 2009
- The Novel, Orally Active, Delta Opioid RWJ-394674 Is Biotransformed to the Potent Mu Opioid RWJ-413216The Journal of Pharmacology and Experimental Therapeutics, 2006
- Evidence for a Selective Role of the δ-Opioid Agonist [8 R-(4b S*,8aα,8aβ,12bβ)]7,10-Dimethyl-1-methoxy-11-(2-methylpropyl)oxycarbonyl 5,6,7,8,12,12b-hexahydro-(9 H)-4,8-methanobenzofuro[3,2-e]pyrrolo[2,3-g]isoquinoline Hydrochloride (SB-235863) in Blocking Hyperalgesia Associated with Inflammatory and Neuropathic Pain ResponsesThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Role of Aromatic Transmembrane Residues of the δ-Opioid Receptor in Ligand RecognitionJournal of Biological Chemistry, 1996
- Properties of TAN-67, a nonpeptide δ-opioid receptor agonist, at cloned human δ-and μ-opioid receptorsEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- DAMGO, a μ‐opioid receptor selective agonist, distinguishes between μ‐ and δ‐opioid receptors around their first extracellular loopsFEBS Letters, 1995
- Cloning of a Delta Opioid Receptor by Functional ExpressionScience, 1992